FDA Accepts Oxylanthanum Carbonate NDA Resubmission for Hyperphosphatemia in CKD Dialysis

The FDA has accepted the resubmitted New Drug Application for oxylanthanum carbonate (OLC), a high-potency lanthanum-based phosphate binder formulated as a small, swallowable pill, advancing it toward potential approval for hyperphosphatemia in dialysis patients with CKD.